



THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

ABCANN GLOBAL CORPORATION ANNOUNCES FILING OF FINAL PROSPECTUS

NAPANEE, ON – February 26, 2018 – ABCann Global Corporation (TSXV:ABCN) (“**ABCann**” or the “**Company**”) is pleased to announce that it has filed and obtained a receipt for a final short form prospectus (the “**Prospectus**”) in respect of its previously announced bought deal public offering (the “**Offering**”) of units and 6.0% unsecured convertible debentures of the Company. The Prospectus was filed in each of the provinces of Canada except Québec and a copy of the Prospectus is available on SEDAR at www.sedar.com.

For further information respecting the Offering, please see the Company’s press release dated January 29, 2018, which is also available on SEDAR.

The Offering is expected to close on or about February 28, 2018 and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

The Prospectus incorporates by reference Management’s Discussion and Analysis for the Company’s wholly-owned subsidiary, ABCann Medicinals Inc., for the years ended December 31, 2016 and 2015, which was prepared and filed by the Company at the request of the Ontario Securities Commission in connection with the filing of the Prospectus. This disclosure was provided pursuant to OSC Staff Notice 51-711 – *Refilings and Corrections of Errors*.

The securities being offered have not been, nor will they be, registered under the United States *Securities Act of 1933*, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any securities in any state in which such offer, solicitation or sale would be unlawful.

About ABCann:

ABCann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.

The Company is expanding its cultivation capacity and pursuing partnerships and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

ON BEHALF OF THE BOARD OF DIRECTORS

“Barry Fishman”

Barry Fishman
CEO and Director

For further information, please contact:



Barry Fishman
CEO and Director
barry.fishman@abcannglobal.com

Michael Bumby
CFO
michael.bumby@abcannglobal.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward Looking Statements

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, regarding the beliefs, plans, expectations or intentions of ABcann and its management regarding the future. Forward looking statements in this news release include statements relating to: the proposed Offering and the required approvals in connection therewith. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Offering may not be completed on the terms or timeline contemplated or at all; the Company may not receive necessary approval for the Offering; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in the Prospectus, which is available on SEDAR, carefully in evaluating the forward-looking statements, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.